Lifitegrast is a medication used to treat dry eye disease. It relieves eye discomfort and inflammation caused by dry eye disease by inhibiting T-cell activation and inflammatory responses.

Lifitegrast(Xiidra):Clinical Uses, Recommended Dosage, Treatment Effect

Lifitegrast is indicated for treating the symptoms and signs of dry eye disease, including eye dryness, pain, stinging, fatigue, foreign body sensation, redness and swelling of the eyes, etc. It can help improve patients' eye comfort and quality of life. It has not yet been marketed in China. This article provides a detailed description of Lifitegrast's indications, usage and dosage, side effects, contraindications, clinical efficacy, etc.

(1) Indications

Lifitegrast is indicated for the treatment of signs and symptoms of dry eye disease (DED).

(2) Usage and Dosage

Recommended Dosage of Lifitegrast

Use a single-dose container to instill one drop of Lifitegrast into each eye, twice a day, with an interval of approximately 12 hours each time. The single-dose container should be discarded immediately after use for each eye.

Contact lenses should be removed before using Lifitegrast, and can be reinserted 15 minutes after use.

(3) Target Population

Adults. Pregnant and lactating women, as well as elderly and pediatric patients, should use the medication under the guidance of a doctor.

(4) Contraindications

Patients with known hypersensitivity to Lifitegrast or any other ingredients in the formulation are contraindicated.

(5) Side Effects

The most common adverse reactions (incidence rate 5%-25%) are instillation site irritation, taste disturbance, and decreased vision.

(6) Precautions

Not yet clear.

(7) Therapeutic Effects

Study Design

The safety and efficacy of Lifitegrast in the treatment of DED were evaluated in a total of 1,181 patients (of whom 1,067 received 5% Lifitegrast), and the use of artificial tears was not allowed during the study.

Study Results

Inferior corneal staining score (ICSS) was recorded at each visit (0 = no staining, 1 = mild/rare punctate lesions, 2 = discrete and countable lesions, 3 = too many lesions to count but not confluent, 4 = confluent).

The mean baseline ICSS was approximately 1.8 in Studies 1 and 2, and approximately 2.4 in Studies 3 and 4. At day 84, three out of the four studies found that Lifitegrast resulted in a greater reduction in ICSS.

(8) Drug Interactions

Not yet clear.

(9) Storage Conditions

Store in the original package at a temperature between 20°C and 25°C.